Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever ...

U.S. FDA granted accelerated approval for Ultragenyx's GENGLYCOS™, the first-ever gene therapy targeting glycogen storage disease type Ia (GSDIa), providing a treatment that reduces reliance on cornstarch and mitigates hypoglycemia risk.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.